Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GlaxoSmithKline ( (GB:GSK) ) has provided an update.
GSK has secured Chinese approval for Exdensur (depemokimab) as an add-on therapy for adults with chronic rhinosinusitis with nasal polyps whose disease remains uncontrolled despite systemic corticosteroids and/or surgery. The drug is the first ultra-long-acting biologic for this indication in China, reflecting GSK’s push to consolidate its leadership in respiratory biologics in a major growth market.
The green light from China’s regulator is backed by phase III ANCHOR data showing statistically significant reductions in nasal polyp size and nasal obstruction with twice-yearly dosing, with a safety profile comparable to placebo plus standard of care. Combined with earlier approvals for severe asthma in China and multiple markets for asthma and CRSwNP, Exdensur’s broader rollout strengthens GSK’s position in type 2 inflammation-driven respiratory diseases and expands treatment options for a large population of patients with persistent, debilitating symptoms.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company focused on respiratory and immunology diseases, developing vaccines, targeted biologics and inhaled medicines. With an industry-leading respiratory portfolio and pipeline, it aims to modify underlying disease mechanisms and improve outcomes for patients with asthma, COPD and related inflammatory conditions worldwide.
Average Trading Volume: 9,547,628
Technical Sentiment Signal: Buy
Current Market Cap: £85.69B
For detailed information about GSK stock, go to TipRanks’ Stock Analysis page.